medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 1

<< Back Next >>

MEDICC Review 2021; 23 (1)

Characterization of Adverse Events Following Childhood Immunizations in Pinar del Río, Cuba

Cruz-Rodríguez E, Galindo-Santana BM, Baldoquín-Rodríguez W, Rodríguez-Velázquez D, Concepción-Díaz D, Luis-Martínez MC

Language: English
References: 52
Page: 35-42
PDF size: 170.41 Kb.


ABSTRACT

INTRODUCTION The Cuban national program for childhood immunizations began in 1962 and has included a surveillance system for monitoring adverse events following immunization since 1999. The expected rate of adverse events following childhood immunization in Cuba is 50 per 100,000 vaccine doses administered. In 2017, Pinar del Río Province reported higher-than-expected rates of adverse events, which motivated this study on their frequency and types.
OBJECTIVE Characterize adverse events following immunization reported in children in Pinar del Río Province in 2017.
METHODS We examined reports of adverse events following immunization in children from 2 months through 14 years of age in Pinar del Río Province, Cuba, from January 1, 2017 through December 31, 2017. We found 487 adverse events that met the criteria established by the national surveillance system. Information was obtained from epidemiological surveys of adverse events following immunization in Pinar del Río Province municipalities. Recorded were age, municipality, signs and symptoms, vaccine type, number of doses, anatomical site and route of vaccine administration, and the institution where the child was vaccinated. We estimated proportions for intensity and frequency related to vaccination, and calculated rates for 100,000 vaccine doses administered. We then compared the rates of observed adverse events with those of expected events.
RESULTS The overall rate of adverse events was 305.6 per 100,000 doses administered. Highest rates were reported in children aged <1 year (580.9 per 100,000 doses administered); in Guane Municipality (610 per 100,000 doses), for the pentavalent (DTwP-HB-Hib) vaccine (1567.7 per 100,000 doses), and in applications to the anterolateral quadrant of the thigh (772.5 per 100,000 doses). Symptoms classifi ed as moderate, common, and general occurred more often, with fever being the most frequent. Severe induration, hypotonic and hyporesponsive episodes, persistent crying and rashes were observed more frequently than expected.
CONCLUSIONS The rate of adverse events following childhood immunization is similar to that reported in other provinces and elsewhere in the world. Of all childhood vaccines, the pentavalent vaccine is the most reactogenic. The absence of serious adverse events demonstrates the safety of childhood immunization in Cuba.


REFERENCES

  1. López Ambrón L, Egües Torres LI, Pérez A, Galindo BM, Galindo MA, Resik S, et al. Experiencia cubana en inmunización, 1962–2016. Rev Panam Salud Pública [Internet]. 2018 [cited 2017 Nov 22];42(34):40–8. Available at: https:// doi.org/10.26633/RPSP.2018.34. Spanish.

  2. Rodríguez A, Zunino C, Speranza N, Fernández S, Varela A, Picón T, et al. Seguimiento de eventos supuestamente atribuibles a la vacunación e inmunización graves notifi cados al Ministerio de Salud Pública entre 2010 y 2014. Rev Méd Urug [Internet]. 2017 [cited 2018 Jun 6];33(1):47–58. Available at: http://www.rmu.org .uy/revista/2017v1/art6.pdf. Spanish.

  3. Secretaría de Salud. Manual de Eventos Supuestamente Atribuibles a la Vacunación o Inmunización. 1st ed [Internet]. Mexico, D.F.: Editorial Soluciones Gráfi cas Lithomat; 2014 Jun [cited 2018 Mar 9]. p. 7–14. Available at: https://www .gob.mx/cms/uploads/attachment/file/287240/ ESAVI_2014.pdf. Spanish.

  4. Spanish Paediatric Association. Manual de vacunas en línea de la AEP [Internet]. Madrid: Spanish Paediatric Association; c1999–2019. Section 1, Chapter 5.2 Efectos adversos de las vacunas; [cited 2017 Dec 15]. Available at: https://vacunasaep.org/documentos/manual/ cap-5. Spanish.

  5. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Iniciativa global sobre la seguridad de las vacunas. Eventos adversos posvacunales; [updated 2015 Apr 1; cited 2017 Dec 12]. Available at: http://www .who.int/vaccine_safety/initiative/detection/AEFI/ es/. Spanish.

  6. World Health Organization. Global Manual on Surveillance of Adverse Events Following Immunization [Internet]. Geneva: World Health Organization; 2014 [cited 2017 Dec 17]. 111 p. Available at: http://www.who.int/vaccine_safety/publications/ Global_Manual_on_Surveillance_of_AEFI.pdf. Spanish.

  7. Ministry of Health (PE). Centro Nacional de Epidemiologia, Prevención y Control de Enfermedades. Vigilancia de ESAVI [Internet]. Lima: Ministry of Health (PE); 2013 [cited 2018 Jun 22]; [about 2 screens]. Available at: http://www.dge .gob.pe/portal/index.php?option=com_content& view=article&id=432&Itemid=109. Spanish.

  8. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Vaccine Safety Basics e-learning course. Adverse events: Classifi cation; 2013 [cited 2018 Feb 27]. Available at: http://vaccine-safety-training.org/ adverse-events-classifi cation.html. Spanish.

  9. Galindo-Santana BM, Cruz-Rodríguez E, López- Ambrón L. A Cuban perspective on the antivaccination movement. MEDICC Rev [Internet]. 2019 Oct [cited 2020 May 27];21(4):64–9. Available at: http://mediccreview.org/a-cuban-perspective-on -the-antivaccination-movement/

  10. Díaz Pinera AM, Cuevas Valdespino IE. Eventos adversos en la vacunación de menores de 2 años, Hospital Pediátrico de Centro Habana (2002- 2007). Rev Cubana Hig Epidemiol [Internet]. 2014 [cited 2017 Nov 7];52(1):81–97. Available at: http://scielo.sld.cu/scielo.php?script=sci_abs tract&pid=S1561-30032014000100008&lng=es &nrm=iso. Spanish.

  11. Galindo BM. Diseño, implementación y evaluación de la vigilancia de eventos adversos a vacunas en Cuba. 1999-2010 [thesis] [Internet]. [Havana]: University of Medical Sciences of Havana; 2017 [cited 2017 Nov 22]. 135 p. Available at: http://tesis.sld.cu/index.php ?P=FullRecord&ID=216. Spanish.

  12. Cruz Martínez G, Verdasquera Corcho D, Corcho Quintero A, Delgado Díaz OL, Díaz Fuentes C, Carbó Riverón M. Eventos adversos de la vacuna cubana antimeningocóccica. Rev Cubana Med Gen Integr [Internet]. 2011 Apr–Jun [cited 2019 Jun 13];27(2):187–96. Available at: http://scielo .sld.cu/scielo.php?script=sci_arttext&pid=S0864 -21252011000200007&nrm=iso. Spanish.

  13. Center for State Control of Medicines and Medical Devices – CECMED (CU). Regulación No. 17 – 2008. Directrices para la investigación de los eventos adversos supuestamente atribuibles a la vacunación o inmunización (ESAVI) [Internet]. Havana: Ministry of Public Health (CU); 2008 [cited 2017 May 14]. 27 p. Available at: http://www .cecmed.cu/reglamentacion-vigilancia?page=1. Spanish.

  14. Galindo-Santana BM, Concepción Díaz D, Galindo- Sardiña MA, Pérez-Rodríguez A, Saíz-Sánchez J. Vaccine-related adverse events in Cuban children, 1999–2008. MEDICC Rev [Internet]. 2012 Jan [cited 2017 Nov 22];14(1):38–43. Available at: https://mediccreview.org/vaccine-related -adverse-events-in-cuban-children-1999-2008/

  15. Galindo Sardiña MA, Galido Santana BM, Pérez Rodríguez A, Santín Peña M. Programa del Sistema de vigilancia de eventos adversos consecutivos a la vacunación [Internet]. Havana: Ministry of Public Health (CU); 1999 [cited 2017 Nov 22]. 21 p. Available at: http://www.cecmed .cu/sites/default/files/adjuntos/vigilancia/farma cov/sist_vig-eventadv_vacunas.pdf. Spanish.

  16. Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, et al. A local reaction at or near injection site: case defi nition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine [Internet]. 2008 [cited 2018 Apr 10];26(52):6800–13. Available at: https://www.sciencedirect.com/science/ article/pii/S0264410X08013868

  17. Ministry of Health (AR) [Internet]. Buenos Aires: Ministry of Health (AR); c2020. Banco de Recursos. La fi ebre como evento adverso después de la inmunización: defi nición de caso y guías para la recogida, análisis y presentación de datos [Internet]. Basel: The Brighton Collaboration; 2003 Mar 13 [cited 2018 Apr 10]. 12 p. Available at: https://bancos.salud.gob.ar/sites/ default/files/2018-10/0000000491cnt-2013-10 _fever_2004_with_2007_addendum_spanish. pdf. Spanish.

  18. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case defi nition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine [Internet]. 2007 [cited 2018 Apr 10];25:5675–84. Available at: https:// docplayer.es/6978087-Anafilaxia-definicion-de -caso-y-lineamientos-para-la-recoleccion-ana lisis-y-presentacion-de-datos-sobre-seguridad -relativa-a-la-inmunizacion.html

  19. Ministry of Health (AR) [Internet]. Buenos Aires: Ministry of Health (AR); c2020. Banco de Recursos. El llanto persistente en lactantes y niños pequeños como evento adverso después de la inmunización: defi nición de caso y guías para la recogida, análisis y presentación de datos; 2003 [cited 2018 Apr 10]. 12 p. Available at: https:// bancos.salud.gob.ar/recurso/el-llanto-persis tente-en-lactantes-y-ninos-pequenos-como -evento-adverso-despues-de-la. Spanish.

  20. Buettcher M, Heininger U, Braun M, Bonhoeffer J, Halperin S, Heijbel H, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization in early childhood: case defi nition and guidelines for data collection, analysis, and presentation. Vaccine [Internet]. 2007 Aug 1 [cited 2018 Apr 10];25(31):5875–81. Available at: https://www.sciencedirect.com/science/ article/pii/S0264410X07005026?via%3Dihub

  21. Bonhoeffer J, Menkes J, Gold MS, De Souza- Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case defi nition and guidelines for data collection, analysis, and presentation. Vaccine [Internet]. 2004 Jan 26 [cited 2018 Apr 10];22(5–6):557–62. Available at: https://jhu .pure.elsevier.com/en/publications/generalized -convulsive-seizure-as-an-adverse-event-follow ing-immu-5

  22. World Health Organization. Guía para las hojas de información de la OMS sobre eventos supuestamente atribuibles a la vacunación o la inmunización (ESAVI) [Internet]. Geneva: World Health Organization; 2012 [cited 2018 May 7]. 3 p. Available at: http://www.who.int/vaccine_safe ty/initiative/tools/Guide_Vaccine_rates_informa tion_sheet_ES.pdf. Spanish.

  23. González Fiallo S, Bell Morales B, García Sanz D, Moreno Gell M. Eventos adversos supuestamente atribuidos a la vacunación o inmunización. Isla de la Juventud, Cuba, enero/2013-octubre/ 2016. VacciMonitor [Internet]. 2017 [cited 2019 Jan 28];26(3):102–9. Available at: http:// www.redalyc.org/articulo.oa?id=203454509005. Spanish.

  24. Mantecón MC. Evaluación del sistema de vigilancia de eventos adversos a la vacunación en la provincia Camagüey, 2016 [thesis]. [Havana]: Dr Pedro Kourí Institute of Tropical Medicine; 2018. Spanish.

  25. Guo B, Page A, Wang H, Taylor R, McIntyre P. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China. Vaccine [Internet]. 2013 Jan 11 [cited 2019 Jan 3];31(4):603–17. Available at: http://dx.doi.org/10.1016/j.vaccine .2012.11.051

  26. Caselli F, Santos CMA, Kalume AG, Deotti SM, da Silva AM, Moreira R, et al. Análise do Sistema de Informação da Vigilância de Eventos Adversos Pós-Vacinação no Brasil, 2014 a 2016. Rev Panam Salud Pública [Internet]. 2018 [cited 2018 Jun 21];42(12):1–12. Available at: https://doi .org/10.26633/RPSP.2018.12. Portuguese.

  27. Law BJ, Lafl èche J, Ahmadipour N, Anyoti H. Canadian Adverse Events Following Immunization SurveillanceSystem (CAEFISS): Annual report for vaccines administered in 2012. CCDR [Internet]. 2014 Dec 4 [cited 2018 Jun 29];40(3). Available at: https://doi.org/10.14745/ccdr.v40 is3a02

  28. Alicino C, Merlano C, Zappettini S, Schiaffi no S, Della Luna G, Accardo C, et al. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. The two-years’ experience of the Liguria Region, Italy. Hum Vaccin Immunother [Internet]. 2015 Jan [cited 2018 Jun 29];11(1):91–4. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4514437/

  29. Kim M-K, Lee YK, Kim TE, Kong I, Yang H-J, Suh ES. Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea. Clin Exp Vaccine Res [Internet]. 2017 Jul [cited 2018 Jun 29];6(2):146–55. Available at: https://www.ncbi .nlm.nih.gov/pmc/articles/PMC5540963/

  30. Dey A, Wang H, Quinn H, Cook J, McCartney K. Annual report: surveillance of adverse events following immunization in Australia, 2015. Commun Dis Intell [Internet]. 2017 Sep [cited 2018 Dec 11];41(3):E264–78. Available at: http://www .health.gov.au/internet/main/publishing.nsf/Content/ cdi4103-l

  31. Deverell M, Phu A, Zurynski Y, Elliott E; APSU Surveillance Studies investigators. Australian Pediatric Surveillance Unit Annual Report, 2016. Commun Dis Intell [Internet]. 2017 Sep [cited 2018 Dec 11];41(3):E288–93. Available at: http:// www.health.gov.au/internet/main/publishing.nsf/ Content/cdi4103-l

  32. Ye Y, Wang CS, Ma YT, Lu MX, Zhang XX, Zhang YY, et al. [Surveillance of adverse events following immunization in Henan Province, China between 2010-2011]. Zhongguo Dang Dai Er Ke Za Zhi [Internet]. 2013 Jun [cited 2018 Dec 12];15(6):466–71. Available at: https://www ncbi.nlm.nih.gov/pubmed/23791064http://www .zgddek.com/EN/abstract/abstract13096.shtml

  33. González V, Gutiérrez S, Quian J. Eventos adversos supuestamente atribuibles a la vacunación e inmunización en hijos de madres infectadas con el virus de la inmunodefi ciencia humana. Arch Pediatr Urug [Internet]. 2013 [cited 2019 Jan 15];84(1):4–9. Available at: http://www.scielo.edu .uy/scielo.php?script=sci_arttext&pid=S1688 -12492013000100002&lng=es. Spanish.

  34. Parentalis [Internet]. [place unknown]: Parentalis. Las vacunas durante el primer año de vida del bebé; 2018 [cited 2018 May 8]. Available at: https://parentalis.com/blog/las-vacunas-durante -el-primer-ano-de-vida-del-bebe/. Spanish.

  35. Arboleda de Chacón LM. Informe anual de ESAVI, Caldas [Internet]. Caldas (CO): Dirección Territorial de Salud; 2014 [cited 2019 Feb 11]. 8 p. Available at: http://observatorio.saluddecaldas .gov.co/desca/vacunacion/ESAVI%202014.pdf. Spanish.

  36. Pérez JA. Evaluación del sistema de vigilancia de eventos adversos a la vacunación. La Lisa, 2015 [thesis]. [Havana]: University of Medical Sciences of Havana; 2017. Spanish.

  37. González Montiel AR. Evaluación del Sistema de Farmacovigilancia utilizado en México, 2012 [thesis]. [Cuernavaca]: National Institute of Public Health (MX); 2012 [cited 2019 Jan 15]. 63 p. Available at: http://catalogoinsp.mx/fi les/ tes/052574.pdf. Spanish.

  38. Ministry of Health of Uruguay. Informe del Sistema de Notifi cación de Efectos Adversos supuestamente atribuibles a la vacunación o inmunización [Internet]. Montevideo: Ministry of Health of Uruguay; 2015 [cited 2018 Dec 9]. 9 p. Available at: https://www.gub.uy/ministerio -salud-publica/sites/ministerio-salud-publica/ files/documentos/publicaciones/Informe%20 ESAVI%202015.pdf. Spanish.

  39. Alfonso OL, Pérez E. Comportamiento del ensayo clínico de la vacuna pentavalente en la Policlínica Docente Área Norte de Placetas. Rev Acta Médica Centro [Internet]. 2010 [cited 2018 Dec 9];4(3). Available at: http://www.revacta medicacentro.sld.cu/index.php/amc/article/ view/514/682. Spanish.

  40. Peña Machado MA, Triana Rodríguez TM, Menéndez J, Mirabal M, Armesto M, Baró Suárez M, et al. Seguimiento de la reactogenicidad de la vacuna DTP cubana, utilizando dos métodos paralelos. VacciMonitor [Internet]. 2005 May [cited 2017 Nov 7];12(1). Available at: https:// www.researchgate.net/profile/Giset_Lopez/ publication/26516949_Seguimiento_de_la _reactogenicidad_de_la_vacuna_DTP_cubana _utilizando_dos_metodos_paralelos/links/54218 3c50cf203f155c6df9d/. Spanish.

  41. Goyetche R, Pérez A, Morena G, Pérez G, Giachetto G, Pírez MC, et al. Efectos adversos asociados a la vacuna antimeningocóccica VA-MENGOCC-BC®. Rev Méd Urug [Internet]. 2004 Aug [cited 2019 Jan 17];20(2):102–5. Available at: http://www.scielo.edu.uy/scielo .php?script=sci_arttext&pid=S1688-0390200 4000200003&lng=es. Spanish.

  42. Zafack Guetsop J, De Serres G, Kiely M, Gariepy MC, Rouleau I, Anne-Marie K, et al. Risk of recurrence of adverse events following immunization: a systematic review. Pediatrics [Internet]. 2017 Sep [cited 2018 Dec 9];140(3):e20163707. Available at: http://pediatrics.aappublications.org/content/ 140/3/e20163707

  43. Ramírez T, Arroyo R, Castro O, Ramírez LA, López JD. Inyecciones intramusculares en niños, aspectos generales y análisis de aplicación en nuestro medio [Internet]. [place unknown]: DocPlayer.es; c2020 [cited 2019 Jan 17]. 5 p. Available at: https://docplayer .es/8145589-Inyecciones-intramusculares-en -ninos-aspectos-generales-y-analisis-de-aplica cion-en-nuestro-medio.html. Spanish.

  44. Principios generales de inmunización. Cap. VIII. In: Normas y Procedimientos del Programa Ampliado de Inmunizaciones (PAI) de Honduras [Internet]. Tegucigalpa: Secretaria de Salud; 2011 Jul [cited 2017 Nov 22]. p. 24–5. Available at: http://www.bvs.hn/Honduras/PAI/ManualNormas yProcedimientos/MNPPAIH1-7.pdf. Spanish.

  45. Merino M, Bravo J. Generalidades sobre vacunas: cosas prácticas. In: AEP. Curso de Actualización Pediatría 2018. Madrid: Lúa Ediciones 3.0; 2018. p. 67–76. Spanish.

  46. Cook IF, Murtagh J. Optimal technique for intramuscular injection of infants and toddlers: a randomized trial. Med J Aust [Internet]. 2005 Jul 18 [cited 2018 Dec 16];183:60–3. Available at: https://www.mja.com.au/journal/2005/183/2/opti mal-technique-intramuscular-injection-infants -and-toddlers-randomised-trial

  47. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ [Internet]. 2000 Oct 14 [cited 2018 Mar 9];321(7266):931–3. Available at: https://www .ncbi.nlm.nih.gov/pmc/articles/pmid/11030682/. Spanish.

  48. Sastoque Díaz LA. Vigilancia en salud pública de los eventos supuestamente atribuibles a la vacunación o inmunización [PowerPoint] [Internet]. Bogotá: National Institute of Health (CO); 2017 Mar 29 [cited 2017 Nov 7]. PowerPoint: 14 slides. Available at: https://www.cali.gov.co/loader.php? lServicio=Tools2&lTipo=descargas&lFuncion=de scargar&idFile=21666. Spanish.

  49. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Vaccine safety basics e-learning course. Adverse events fallowing immunization; 2018 [cited 2018 Jun 20]. Available at: http://vaccine-safety-training.org/ vaccine-reactions.html

  50. Clínica Alemana [Internet]. Santiago de Chile: Clínica Alemana; c2020. Los efectos secundarios de las vacunas; 2006 [updated 2019 Dec 25; cited 2018 Dec 12]. Available at: https://portal .alemana.cl/wps/wcm/connect/Internet/Home/ blog-de-noticias/Ano+2011/01/Los+efectos+sec undarios+de+las+vacunas. Spanish.

  51. Formulario Nacional de Medicamentos [Internet]. Havana: INFOMED; c2020. Vacuna Muerta Pentavalente Heberpenta; 2013 [cited 2018 Dec 9]. Available at: http://fnmedicamentos.sld.cu/index .php?P=FullRecord&ID=391. Spanish.

  52. CIOMS Guide to vaccine safety communication. Report by topic group 3 of the CIOMS Working Group on Vaccine Safety [Internet]. Geneva: Council for International Organizations of Medical Sciences; 2018 [cited 2018 Feb 27]. 66 p. Available at: https://cioms.ch/wp-content/ uploads/2019/05/WEB-CIOMS-Communication -Guide-2018.pdf




2020     |     www.medigraphic.com